Incruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Incruse received US and EU approvals for use in COPD in April 2014. GlaxoSmithKline has also developed umeclidinium in combination with the long-acting beta 2 agonist (LABA) vilanterol; the LABA/LAMA combination is marketed under the brand name Anoro.
LIST OF FIGURES 8 Figure 1: Incruse for COPD – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Incruse for COPD
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Incruse for COPD
13 Figure 4: Incruse sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Incruse drug profile
7 Table 2: Incruse Phase III data in COPD
14 Table 3: Incruse sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.